When does our brain start getting 'old'? Charting the lifespan trajectories of cognitive control
Peer-Reviewed Publication
Updates every hour. Last Updated: 27-Dec-2025 11:11 ET (27-Dec-2025 16:11 GMT/UTC)
Bodily functions rise and decline with age, and the brain is no exception. However, the exact trajectory of our brain activity during controlled behavior remains unclear. A recent study published in Science Bulletin by Zhenghan Li et al. explores this issue. They found that brain activities related to cognitive control follow an inverted U-shape in the whole lifespan, peaking between ages 27 and 36. These insights may help develop strategies for enhancing brain health and optimizing cognitive function across various age groups.
Despite nearly 90% of pet owners viewing their animals as family members, few understand the emotional and practical complexities of providing animal care that veterinarians navigate daily.
A multicenter study published in the Journal of Pancreatology reveals that postoperative exocrine pancreatic insufficiency (EPI) peaks within three months after pancreatic surgery in patients with benign or low-malignant tumors.
The research highlights that pancreatic enzyme replacement therapy (PERT) significantly improves symptoms in patients undergoing pancreatoduodenectomy (PD), while its duration may be reduced for those having distal pancreatectomy (DP). This study provides crucial insights for clinicians to enhance postoperative care and quality of life.
In the weeks after the October 7 Hamas attacks, many Israelis faced not only the trauma of war but also a surge of online hate. A new study from the Hebrew University finds that frequent exposure to such digital vitriol is linked to higher PTSD symptoms, especially for those who struggle to regulate their emotions, underscoring how today’s conflicts can wound both on the battlefield and on the screen.
EurekAlert-Style Summary
Technion researchers uncover surprising two-way links between heart disease and cancer
A new study from the Technion–Israel Institute of Technology reveals unexpected interactions between cancer and heart disease—findings that could pave the way for innovative therapies for both conditions. Led by Prof. Ami Aronheim, dean of the Ruth and Bruce Rappaport Faculty of Medicine, the research shows that in the absence of anti-cancer treatments, cancer development may actually improve heart function and reduce cardiac fibrosis, the stiffening of heart tissue.
Published in JACC: CardioOncology, the work synthesizes recent breakthroughs from Prof. Aronheim and doctoral students Lama Awwad and Laris Achlaug, who explore the bidirectional relationship between heart failure and cancer. While it has long been known that many cancer therapies damage the heart, the team aims to identify additional biological links and unravel the underlying mechanisms connecting the two diseases.
Heart disease and cancer share numerous risk factors—including smoking, obesity, diabetes, and high blood pressure—as well as biological pathways involving chronic inflammation, immune-system changes, and extracellular matrix remodeling. Previous studies from Aronheim’s group showed that heart disease can accelerate cancer growth and metastasis.
The new findings highlight a significant clinical gap: no current treatments can reverse cardiac fibrosis or directly improve the heart muscle’s contractile strength. By revealing how cancer may modulate these processes, the study opens the door to potential new therapeutic strategies for patients with either condition.
This research was supported by the Rappaport Family Institute for Research in the Medical Sciences.